Putin praises Hermitage Museum for its efforts in restoring PalmyraSociety & Culture December 02, 21:03
Lavrov says 'Crimea is not a problem, it is a part of Russia'Russian Politics & Diplomacy December 02, 20:42
Russian top diplomat says Syria cannot repeat Libya’s fateRussian Politics & Diplomacy December 02, 19:53
Key facts about the '90s price liberalization in RussiaBusiness & Economy December 02, 19:46
Russia's antimonopoly watchdog: Google will not 'get off with fines'Business & Economy December 02, 19:32
Lavrov wonders why UN is not using Castello Road to deliver humanitarian aid to AleppoRussian Politics & Diplomacy December 02, 19:24
Top diplomat calls to motivate Libyan parties towards mutually acceptable agreementsRussian Politics & Diplomacy December 02, 19:02
Russia's top diplomat says he urged de Mistura not to delay intra-Syrian talksRussian Politics & Diplomacy December 02, 18:58
Source says Hvorostovsky’s debut at Bolshoi canceled due to health issuesSociety & Culture December 02, 18:53
MOSCOW, September 02. /ITAR-TASS/. The Russian government’s foreign investment commission has cleared US company Abbot purchase of Russia’s major pharmaceutical producer Veropharm for $650 million, Director of the Federal Antimonopoly Service Igor Artemyev said Tuesday.
“The first deal, which has been cleared by the commission today, is large US company Abbot buying Veropharm that produces many important medicines for the treatment of oncological diseases, acute leukemia and others,” Artemyev said.
He also said the sum of the deal comprises the cost of Veropharm and its affiliates, while $250 million more will be allocated for the construction of new production sites increasing the production’s localization.
On June 24, Abbott said that it will acquire Veropharm from its largest shareholder Roman Avdeyev for $13.6-17 billion rubles. The purchase price will depend on the stake which Avdeyev’s holding Garden Hills, which currently owns about 81% in Veropharm, can consolidate at the moment when the contract is signed.
Abbot also agreed to repay Veropharm’s debts of 4.7 billion rubles, or $136 million.